Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
OBJECTIVE
Little information is available about changes in renal function after cisplatin-based chemotherapy (CBCT) in patients with a solitary kidney. The authors evaluated the renal safety and efficacy of CBCT after nephroureterectomy for upper urinary tract-urothelial carcinoma (UUT-UC).


METHODS
The data of patients who underwent nephroureterectomy for UUT-UC and received CBCT for adjuvant and/or palliative treatment were reviewed. Renal function changes and renal function-related adverse events (AEs) were analyzed, and objective tumor responses were assessed.


RESULTS
Sixty patients were enrolled, and a median of 6 cycles (1-22) of CBCT were administered. After the 3rd cycle of CBCT, serum creatinine levels were significantly higher than at baseline, whereas mean creatinine clearances and estimated glomerular filtration rates were significantly lower. These renal function indicators also tended to be lower than baseline after the 6th-21st cycles, but these decreases were not significant. Significant AEs (≥grade 2) occurred in 10 patients (16.7%), and serious AEs (≥grade 3) developed in two that required temporary hemodialysis. Univariate analysis revealed that a low estimated glomerular filtration rate at baseline was related to the occurrence of a significant renal AE with borderline significance (Hazard ratio = 3.284, P = 0.100). The overall tumor response rate was 30.2%, and tumor response rates of 1st, 2nd, and 3rd line therapies were 36.4, 25.0, and 12.5%, respectively.


CONCLUSIONS
Cisplatin-based chemotherapy can be administered in the majority of patients with UUT-UC with a solitary kidney after nephroureterectomy without inducing a serious AE, and provides acceptable efficacy.
Cho
Kang Su
KS
Urologic Oncology Clinic, Center for Prostate Cancer, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 410-769, Republic of Korea.
Joung
Jae Young
JY
Seo
Ho Kyung
HK
Cho
In-Chang
IC
Chung
Han Soo
HS
Chung
Jinsoo
J
Lee
Kang Hyun
KH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D016208:Databases, Factual; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D007677:Kidney Function Tests; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000379:methods; D010166:Palliative Care / Q000379:methods; D016896:Treatment Outcome; D014516:Ureteral Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000970:Antineoplastic Agents; D003404:Creatinine; D002945:Cisplatin